Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models.

van den Brand JAJG, Dijkstra TMH, Wetzels J, Stengel B, Metzger M, Blankestijn PJ, Lambers Heerspink HJ, Gansevoort RT.

PLoS One. 2019 May 9;14(5):e0216559. doi: 10.1371/journal.pone.0216559. eCollection 2019.

2.

Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.

Savonitto S, Morici N, Nozza A, Cosentino F, Perrone Filardi P, Murena E, Morocutti G, Ferri M, Cavallini C, Eijkemans MJ, Stähli BE, Schrieks IC, Toyama T, Lambers Heerspink HJ, Malmberg K, Schwartz GG, Lincoff AM, Ryden L, Tardif JC, Grobbee DE.

Diab Vasc Dis Res. 2018 Jan;15(1):14-23. doi: 10.1177/1479164117735493. Epub 2017 Oct 20.

PMID:
29052439
3.

Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.

Kwakernaak AJ, Roksnoer LC, Lambers Heerspink HJ, van den Berg-Garrelds I, Lochorn GA, van Embden Andres JH, Klijn MA, Kobori H, Danser AH, Laverman GD, Navis GJ.

PLoS One. 2017 Jan 24;12(1):e0169258. doi: 10.1371/journal.pone.0169258. eCollection 2017.

4.

Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.

Keyzer CA, van Breda GF, Vervloet MG, de Jong MA, Laverman GD, Hemmelder MH, Janssen WM, Lambers Heerspink HJ, Kwakernaak AJ, Bakker SJ, Navis G, de Borst MH; Holland Nephrology Study (HONEST) Network.

J Am Soc Nephrol. 2017 Apr;28(4):1296-1305. doi: 10.1681/ASN.2016040407. Epub 2016 Nov 17.

5.

Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population-based cohort study.

Meems LM, Brouwers FP, Joosten MM, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, Gansevoort RT, van Gilst WH, van der Harst P, de Boer RA.

ESC Heart Fail. 2016 Sep;3(3):189-197. Epub 2016 Apr 26.

6.

Association of Skin Autofluorescence Levels With Kidney Function Decline in Patients With Peripheral Artery Disease.

Schutte E, de Vos LC, Lutgers HL, Lambers Heerspink HJ, Wolffenbuttel BH, Vart P, Zeebregts CJ, Gansevoort RT, Lefrandt JD.

Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1709-14. doi: 10.1161/ATVBAHA.116.307771. Epub 2016 Jun 30.

PMID:
27365407
7.

High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes.

van den Born JC, Frenay AR, Bakker SJ, Pasch A, Hillebrands JL, Lambers Heerspink HJ, van Goor H.

Nitric Oxide. 2016 May 1;55-56:18-24. doi: 10.1016/j.niox.2016.03.001. Epub 2016 Mar 4.

PMID:
26952289
8.

Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium Intake.

Keyzer CA, Lambers-Heerspink HJ, Joosten MM, Deetman PE, Gansevoort RT, Navis G, Kema IP, de Zeeuw D, Bakker SJ, de Borst MH; PREVEND Study Group.

Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2119-27. doi: 10.2215/CJN.03830415. Epub 2015 Oct 8.

9.

Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes.

Schievink B, Kröpelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J, Vemer P, de Zeeuw D, Lambers Heerspink HJ.

Diabetes Obes Metab. 2016 Jan;18(1):64-71. doi: 10.1111/dom.12583. Epub 2015 Nov 27.

PMID:
26434564
10.

Erratum to: Abstracts of the 51st Annual Meeting of the EASD, Stockholm 2015. 'Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive patients with diabetes'.

Lambers Heerspink HJ, Johnsson E, Gause-Nilsson I, Sjöström C.

Diabetologia. 2015 Dec;58(12):2901. doi: 10.1007/s00125-015-3765-7. No abstract available.

PMID:
26404064
11.

The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention.

Özyilmaz A, Boersma C, Visser ST, Postma MJ, de Jong-van den Berg LT, Lambers-Heerspink HJ, de Jong PE, Gansevoort RT.

Eur J Prev Cardiol. 2016 May;23(8):847-55. doi: 10.1177/2047487315604310. Epub 2015 Sep 10.

PMID:
26358992
12.

Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores.

Schievink B, Mol PG, Lambers Heerspink HJ.

Curr Opin Nephrol Hypertens. 2015 Nov;24(6):492-7. doi: 10.1097/MNH.0000000000000159. Review.

PMID:
26335552
13.

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.

Schievink B, de Zeeuw D, Smink PA, Andress D, Brennan JJ, Coll B, Correa-Rotter R, Hou FF, Kohan D, Kitzman DW, Makino H, Parving HH, Perkovic V, Remuzzi G, Tobe S, Toto R, Hoekman J, Lambers Heerspink HJ.

Eur J Prev Cardiol. 2016 May;23(7):758-68. doi: 10.1177/2047487315598709. Epub 2015 Jul 30.

PMID:
26229089
14.

Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression.

Schutte E, Gansevoort RT, Benner J, Lutgers HL, Lambers Heerspink HJ.

Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv96-104. doi: 10.1093/ndt/gfv119. Review.

PMID:
26209744
15.

Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes.

Pena MJ, de Zeeuw D, Mischak H, Jankowski J, Oberbauer R, Woloszczuk W, Benner J, Dallmann G, Mayer B, Mayer G, Rossing P, Lambers Heerspink HJ.

Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv86-95. doi: 10.1093/ndt/gfv252. Review.

PMID:
26209743
16.

Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine.

Lambers Heerspink HJ, Oberbauer R, Perco P, Heinzel A, Heinze G, Mayer G, Mayer B.

Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv105-112. doi: 10.1093/ndt/gfv210. Review.

PMID:
26209732
17.

Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension: The Prevention of Renal and Vascular End-Stage Disease Study.

van Ballegooijen AJ, Gansevoort RT, Lambers-Heerspink HJ, de Zeeuw D, Visser M, Brouwer IA, Kema IP, de Borst MH, Bakker SJ, Joosten MM.

Hypertension. 2015 Sep;66(3):563-70. doi: 10.1161/HYPERTENSIONAHA.115.05837. Epub 2015 Jul 20.

PMID:
26195480
18.

Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study.

Vart P, Scheven L, Lambers Heerspink HJ, de Jong PE, de Zeeuw D, Gansevoort RT; PREVEND Study Group and the RENAAL Investigators.

Am J Kidney Dis. 2016 Jan;67(1):70-8. doi: 10.1053/j.ajkd.2015.05.025. Epub 2015 Jul 15.

PMID:
26188433
19.

The blood pressure lowering potential of sulodexide--a systematic review and meta-analysis.

Olde Engberink RH, Rorije NM, Lambers Heerspink HJ, De Zeeuw D, van den Born BJ, Vogt L.

Br J Clin Pharmacol. 2015 Dec;80(6):1245-53. doi: 10.1111/bcp.12722. Epub 2015 Aug 24. Review.

20.

Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.

Kohan DE, Lambers Heerspink HJ, Coll B, Andress D, Brennan JJ, Kitzman DW, Correa-Rotter R, Makino H, Perkovic V, Hou FF, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D.

Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1568-74. doi: 10.2215/CJN.00570115. Epub 2015 Jul 7.

21.

Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).

Schutte E, Lambers Heerspink HJ, Lutgers HL, Bakker SJ, Vart P, Wolffenbuttel BH, Umanath K, Lewis JB, de Zeeuw D, Gansevoort RT.

Am J Kidney Dis. 2015 Sep;66(3):450-8. doi: 10.1053/j.ajkd.2015.03.032. Epub 2015 May 16.

PMID:
25987260
22.

A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes.

Pena MJ, Heinzel A, Heinze G, Alkhalaf A, Bakker SJ, Nguyen TQ, Goldschmeding R, Bilo HJ, Perco P, Mayer B, de Zeeuw D, Lambers Heerspink HJ.

PLoS One. 2015 May 14;10(5):e0120995. doi: 10.1371/journal.pone.0120995. eCollection 2015.

23.

Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View.

Lambers Heerspink HJ, Gansevoort RT.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1079-88. doi: 10.2215/CJN.11511114. Epub 2015 Apr 17. Review.

24.

Rebuttal of the Con View: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD.

Lambers Heerspink HJ, Gansevoort RT.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1099. doi: 10.2215/CJN.02760315. Epub 2015 Apr 17.

25.

The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.

Schievink B, de Zeeuw D, Parving HH, Rossing P, Lambers Heerspink HJ.

Br J Clin Pharmacol. 2015 Oct;80(4):678-86. doi: 10.1111/bcp.12655. Epub 2015 May 28.

26.

Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol.

Keyzer CA, de Jong MA, Fenna van Breda G, Vervloet MG, Laverman GD, Hemmelder M, Janssen WM, Lambers Heerspink HJ, Navis G, de Borst MH; Holland Nephrology Study (HONEST) Network.

Nephrol Dial Transplant. 2016 Jul;31(7):1081-7. doi: 10.1093/ndt/gfv033. Epub 2015 Mar 4. Review.

PMID:
25744274
27.

[The prevention of renal failure has to improve].

Gansevoort RT, Lambers Heerspink HJ, de Jong PE.

Ned Tijdschr Geneeskd. 2015;159:A8472. Dutch.

PMID:
25690073
28.

Clinical trials: New nonabsorbable potassium-exchange resins in hyperkalaemia.

Roscioni SS, Lambers Heerspink HJ.

Nat Rev Nephrol. 2015 Apr;11(4):205-6. doi: 10.1038/nrneph.2014.252. Epub 2015 Jan 20. No abstract available.

PMID:
25599617
29.

Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review.

Martono DP, Lub R, Lambers Heerspink HJ, Hak E, Wilffert B, Denig P.

Diabet Med. 2015 Jul;32(7):853-64. doi: 10.1111/dme.12688. Epub 2015 Feb 9. Review.

PMID:
25582542
30.

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.

Jun M, Turin TC, Woodward M, Perkovic V, Lambers Heerspink HJ, Manns BJ, Tonelli M, Hemmelgarn BR.

J Am Soc Nephrol. 2015 Sep;26(9):2289-302. doi: 10.1681/ASN.2014040396. Epub 2015 Jan 2. Review.

31.

GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials.

Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, Coresh J, Levey AS, Inker LA.

Am J Kidney Dis. 2014 Dec;64(6):860-6. doi: 10.1053/j.ajkd.2014.08.018. Epub 2014 Oct 16.

PMID:
25441439
32.

GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials.

Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS.

Am J Kidney Dis. 2014 Dec;64(6):848-59. doi: 10.1053/j.ajkd.2014.08.017. Epub 2014 Oct 16.

PMID:
25441438
33.

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop.

Romero K, Sinha V, Allerheiligen S, Danhof M, Pinheiro J, Kruhlak N, Wang Y, Wang SJ, Sauer JM, Marier JF, Corrigan B, Rogers J, Lambers Heerspink HJ, Gumbo T, Vis P, Watkins P, Morrison T, Gillespie W, Gordon MF, Stephenson D, Hanna D, Pfister M, Lalonde R, Colatsky T.

J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):545-52. doi: 10.1007/s10928-014-9390-0. Epub 2014 Oct 7.

PMID:
25288257
34.

Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.

Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH; NIGRAM Consortium.

Am J Kidney Dis. 2015 Feb;65(2):259-66. doi: 10.1053/j.ajkd.2014.07.022. Epub 2014 Sep 30.

PMID:
25278093
35.

Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.

McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D.

Am J Kidney Dis. 2014 Nov;64(5):714-22. doi: 10.1053/j.ajkd.2014.06.008. Epub 2014 Jul 24.

PMID:
25064674
36.

Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease.

Lambers Heerspink HJ, Gaillard CJ, Gansevoort RT.

Ann Intern Med. 2014 Jul 1;161(1):82-3. doi: 10.7326/L14-5013-3. No abstract available.

PMID:
24979457
37.

Microalbuminuria: target for renoprotective therapy PRO.

Roscioni SS, Lambers Heerspink HJ, de Zeeuw D.

Kidney Int. 2014 Jul;86(1):40-9. doi: 10.1038/ki.2013.490. Epub 2014 Apr 23. Review. Erratum in: Kidney Int. 2015 Jan;87(1):243-4.

38.

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH.

J Am Soc Nephrol. 2014 May;25(5):1083-93. doi: 10.1681/ASN.2013080830. Epub 2014 Apr 10.

39.

Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.

Riphagen IJ, Deetman PE, Bakker SJ, Navis G, Cooper ME, Lewis JB, de Zeeuw D, Lambers Heerspink HJ.

Diabetes. 2014 Aug;63(8):2845-53. doi: 10.2337/db13-1652. Epub 2014 Mar 27.

40.

Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus.

Pena MJ, Lambers Heerspink HJ, Hellemons ME, Friedrich T, Dallmann G, Lajer M, Bakker SJ, Gansevoort RT, Rossing P, de Zeeuw D, Roscioni SS.

Diabet Med. 2014 Sep;31(9):1138-47. doi: 10.1111/dme.12447. Epub 2014 Apr 21.

PMID:
24661264
41.

Sodium excretion and risk of developing coronary heart disease.

Joosten MM, Gansevoort RT, Mukamal KJ, Lambers Heerspink HJ, Geleijnse JM, Feskens EJ, Navis G, Bakker SJ; PREVEND Study Group.

Circulation. 2014 Mar 11;129(10):1121-8. doi: 10.1161/CIRCULATIONAHA.113.004290. Epub 2014 Jan 14.

PMID:
24425751
42.

Predictors of congestive heart failure after treatment with an endothelin receptor antagonist.

Hoekman J, Lambers Heerspink HJ, Viberti G, Green D, Mann JF, de Zeeuw D.

Clin J Am Soc Nephrol. 2014 Mar;9(3):490-8. doi: 10.2215/CJN.07040713. Epub 2014 Jan 9.

43.

Estimated albumin excretion rate versus urine albumin-creatinine ratio for the assessment of albuminuria: a diagnostic test study from the Prevention of Renal and Vascular Endstage Disease (PREVEND) Study.

Abdelmalek JA, Gansevoort RT, Lambers Heerspink HJ, Ix JH, Rifkin DE.

Am J Kidney Dis. 2014 Mar;63(3):415-21. doi: 10.1053/j.ajkd.2013.10.061. Epub 2013 Dec 21.

44.

Are renin-angiotensin-aldosterone system inhibitors lifesaving in chronic kidney disease?

Damman K, Lambers-Heerspink HJ.

J Am Coll Cardiol. 2014 Feb 25;63(7):659-660. doi: 10.1016/j.jacc.2013.10.051. Epub 2013 Nov 21. No abstract available.

45.

Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).

Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D.

Am J Kidney Dis. 2014 Feb;63(2):244-50. doi: 10.1053/j.ajkd.2013.09.016. Epub 2013 Nov 6.

PMID:
24210590
46.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators.

N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9.

47.

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.

Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A, Krauth M, Linde P, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Christ-Schmidt H, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, de Zeeuw D.

Nephrol Dial Transplant. 2013 Nov;28(11):2841-50. doi: 10.1093/ndt/gft445.

PMID:
24169612
48.

The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers.

Smink PA, Miao Y, Eijkemans MJ, Bakker SJ, Raz I, Parving HH, Hoekman J, Grobbee DE, de Zeeuw D, Lambers Heerspink HJ.

Clin Pharmacol Ther. 2014 Feb;95(2):208-15. doi: 10.1038/clpt.2013.191. Epub 2013 Sep 25.

PMID:
24067744
49.

Cardiovascular disease in patients with chronic kidney disease.

Pilmore H, Dogra G, Roberts M, Lambers Heerspink HJ, Ninomiya T, Huxley R, Perkovic V.

Nephrology (Carlton). 2014 Jan;19(1):3-10. doi: 10.1111/nep.12148. No abstract available.

PMID:
23927055
50.

Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial).

Schroten NF, Ruifrok WP, Kleijn L, Dokter MM, Silljé HH, Lambers Heerspink HJ, Bakker SJ, Kema IP, van Gilst WH, van Veldhuisen DJ, Hillege HL, de Boer RA.

Am Heart J. 2013 Aug;166(2):357-364.e2. doi: 10.1016/j.ahj.2013.05.009. Epub 2013 Jun 24.

PMID:
23895820

Supplemental Content

Loading ...
Support Center